Skip to content

Feasibility of Systematic Handgrip Strength (HGS) Testing and Short-term Changes in Muscle Strength in Digestive Cancer Patients Treated by Chemotherapy

Feasibility of Systematic Handgrip Strength (HGS) Testing and Short-term Changes in Muscle Strength in Digestive Cancer Patients Treated by Chemotherapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02797197
Acronym
FIGHTDIGO
Enrollment
201
Registered
2016-06-13
Start date
2016-05-18
Completion date
2017-02-15
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Handgrip Strength Test, Sarcopenia, Digestive Cancer, Muscle Strength, Chemotherapy

Brief summary

Sarcopenia is defined as a loss in skeletal muscle mass and function (strength and/or performance). There is a high prevalence in elderly and in patients with cancer. Several mechanisms are known to explain sarcopenia (inflammation, neurodegenerative process, hormonal disorders, lack of exercise, malnutrition). The consequences were analysed in several studies where sarcopenia appeared to be an independent factor of mortality, and associated with cancer-related fatigue, nosocomial infections, cardio-vascular diseases, and chemotherapy toxicities. Diagnosis is based on the measure of the muscle mass performing an abdominal computed-tomography (CT) scan, and on the measure of the muscle strength using the handgrip test with a Jamar® hydraulic hand dynamometer. CT scan is more invasive and less easy to reach than handgrip test. This test is used to be performing in elderly but not in cancer patients having chemotherapy. Present prospective study explored the feasibility of systematic handgrip strength testing and short-term changes in muscle strength in digestive cancer patients treated by chemotherapy.

Interventions

DRUGchemotherapy

Sponsors

CHU de Reims
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients with digestive cancer having a chemotherapy and/or biotherapy in the department of Reims * \> 18 years old * after patient agreement * linked to social security system

Exclusion criteria

* legal guardianship * \< 18 years old * neuro-muscular issue

Design outcomes

Primary

MeasureTime frame
number of patients having at least one handgrip strength test among all hospitalized cancer patients undergoing chemotherapy6 months
Evaluation of handgrip test by patientsafter 3 months
Evaluation of handgrip test by staff (nurses, interns, students)6 months
number of handgrip strength test measures per patient, number of handgrip test measures compared to the number of day hospitalisations, number of patients who had all of the measures, between 50 and 100% of measures, less than 50% of measures6 months

Secondary

MeasureTime frame
to study the association between hand grip strength test and tolerance to chemotherapy6 months
to study the association between the evolution of hand grip strength test and the evolution of nutritional indices (anthropometric and biologic)6 months
to follow the short term evolution of hand grip strength test during 6 months in patients undergoing chemotherapy6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026